On June 17th, BMS announced at the EHA 2018 annual meeting that phase II ELOQUENT-3 study reached the primary endpoint, Empititi (elotuzumab) combined with poloximatil and low-dose dexamethasone (EPd regimen) compared to using pomametide alone And dexamethasone (Pd regimen) can significantly improve progression-free survival in patients with relapsed or refractory… Continue Reading Empliciti has significant benefits in the treatment of multiple myeloma with a 46% lower risk of disease progression

On May 8th, Johnson & Johnson announced that Darzalex (daratumumab) new indication has received FDA approval for the combined use of bortezomib, melphalan and prednisone for first-line treatment of newly diagnosed unfit autologous stem cell transplantation (ASCT) multiple myeloma patient. In this way, Darzalex began with the FDA approval in… Continue Reading Johnson’s blockbuster Darzalex has been upgraded to receive first-line treatment for multiple myeloma.

On April 17, takeda announced “Ixazomib citrate capsules obtains the national food and drug supervision and administration bureau (CFDA, now the SDA) issued by the drug import registration certificate, allowed to joint drug lenalidomide and dexamethasone for the treatment of always get at least one line treatment of multiple myeloma… Continue Reading Ixazomib was approved by the CFDA for approval, and the import of new drugs was accelerated in China.